IT1261949B - Composizione terapeutica a base di interferone umano, impiego di interferone umano in tale composizione e relativo metodo. - Google Patents

Composizione terapeutica a base di interferone umano, impiego di interferone umano in tale composizione e relativo metodo.

Info

Publication number
IT1261949B
IT1261949B ITRM930840A ITRM930840A IT1261949B IT 1261949 B IT1261949 B IT 1261949B IT RM930840 A ITRM930840 A IT RM930840A IT RM930840 A ITRM930840 A IT RM930840A IT 1261949 B IT1261949 B IT 1261949B
Authority
IT
Italy
Prior art keywords
human
interferone
composition
related method
therapeutic composition
Prior art date
Application number
ITRM930840A
Other languages
English (en)
Italian (it)
Inventor
Valtuena Jesus Prieto
Ruiz Oscar Beloqui
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of ITRM930840A0 publication Critical patent/ITRM930840A0/it
Publication of ITRM930840A1 publication Critical patent/ITRM930840A1/it
Application granted granted Critical
Publication of IT1261949B publication Critical patent/IT1261949B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/34—Trocars; Puncturing needles
    • A61B17/3417—Details of tips or shafts, e.g. grooves, expandable, bendable; Multiple coaxial sliding cannulas, e.g. for dilating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/34—Trocars; Puncturing needles
    • A61B17/3476—Powered trocars, e.g. electrosurgical cutting, lasers, powered knives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/34—Trocars; Puncturing needles
    • A61B17/3494—Trocars; Puncturing needles with safety means for protection against accidental cutting or pricking, e.g. limiting insertion depth, pressure sensors
    • A61B17/3496—Protecting sleeves or inner probes; Retractable tips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14—Probes or electrodes therefor
    • A61B18/1487—Trocar-like, i.e. devices producing an enlarged transcutaneous opening
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/32—Surgical cutting instruments
    • A61B17/3205—Excision instruments
    • A61B17/3207—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
    • A61B17/320725—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions with radially expandable cutting or abrading elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/32—Surgical cutting instruments
    • A61B17/3205—Excision instruments
    • A61B17/3207—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
    • A61B17/32075—Pullback cutting; combined forward and pullback cutting, e.g. with cutters at both sides of the plaque
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/32—Surgical cutting instruments
    • A61B17/3209—Incision instruments
    • A61B17/3211—Surgical scalpels, knives; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/34—Trocars; Puncturing needles
    • A61B17/3474—Insufflating needles, e.g. Veress needles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00053—Mechanical features of the instrument of device
    • A61B2018/00184—Moving parts
    • A61B2018/0019—Moving parts vibrating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M13/00—Insufflators for therapeutic or disinfectant purposes, i.e. devices for blowing a gas, powder or vapour into the body
    • A61M13/003—Blowing gases other than for carrying powders, e.g. for inflating, dilating or rinsing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Otolaryngology (AREA)
  • Plasma & Fusion (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ITRM930840A 1992-12-22 1993-12-21 Composizione terapeutica a base di interferone umano, impiego di interferone umano in tale composizione e relativo metodo. IT1261949B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929226729A GB9226729D0 (en) 1992-12-22 1992-12-22 Therapeutic combination

Publications (3)

Publication Number Publication Date
ITRM930840A0 ITRM930840A0 (it) 1993-12-21
ITRM930840A1 ITRM930840A1 (it) 1995-06-21
IT1261949B true IT1261949B (it) 1996-06-04

Family

ID=10727038

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM930840A IT1261949B (it) 1992-12-22 1993-12-21 Composizione terapeutica a base di interferone umano, impiego di interferone umano in tale composizione e relativo metodo.

Country Status (24)

Country Link
US (1) US5830455A (Sortimente)
EP (1) EP0675730B1 (Sortimente)
JP (2) JP2849214B2 (Sortimente)
KR (1) KR100309059B1 (Sortimente)
CN (1) CN1094642A (Sortimente)
AT (1) ATE199643T1 (Sortimente)
AU (1) AU680858B2 (Sortimente)
CA (1) CA2152389A1 (Sortimente)
DE (1) DE69330032T2 (Sortimente)
ES (1) ES2156150T3 (Sortimente)
FR (1) FR2699407A1 (Sortimente)
GB (1) GB9226729D0 (Sortimente)
HR (1) HRP931510A2 (Sortimente)
HU (1) HUT72965A (Sortimente)
IL (1) IL108114A (Sortimente)
IT (1) IT1261949B (Sortimente)
MY (1) MY141415A (Sortimente)
NO (1) NO952469L (Sortimente)
PL (1) PL309398A1 (Sortimente)
RU (1) RU2145235C1 (Sortimente)
TW (1) TW286283B (Sortimente)
WO (1) WO1994014473A1 (Sortimente)
YU (1) YU79393A (Sortimente)
ZA (1) ZA939583B (Sortimente)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508031A (en) * 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
DE4325547C2 (de) * 1993-07-29 1997-11-27 Max Planck Gesellschaft Verwendung von Thiolverbindungen zur Therapie von Hepatitis-_Viren-induzierten Erkrankungen
US6020205A (en) * 1998-04-10 2000-02-01 Immunosciences Lab, Inc. Determination of intracellular antioxidant levels
RU2156134C2 (ru) * 1998-05-12 2000-09-20 ООО "Формавит" Биофармацевтический препарат на основе живой культуры bacillus и способ лечения заболевания инфекционной природы
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
IL153020A0 (en) 2000-05-26 2003-06-24 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
US6878364B2 (en) * 2000-12-01 2005-04-12 Cornell Research Foundation, Inc. Animal model for flaviviridae infection
US6759061B2 (en) * 2001-08-31 2004-07-06 Renew Life, Inc. Liver function improvement formulation
RU2242243C2 (ru) * 2001-09-27 2004-12-20 Вертелецкий Павел Васильевич Композиции и способы потенцирования терапевтических эффектов интерферонов
JP2005504087A (ja) * 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド ４’が修飾されたヌクレオシドを使用するｃ型肝炎ウイルス治療のための方法および組成物
US20030158213A1 (en) * 2001-11-16 2003-08-21 Freeman Bruce A. Xanthine oxidase inhibition as a strategy to alleviate oxidative impairment of vascular function
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
EP1523489B1 (en) 2002-06-28 2014-03-12 IDENIX Pharmaceuticals, Inc. Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
CN1678326A (zh) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
JP2004155777A (ja) * 2002-10-16 2004-06-03 Asahi Kasei Pharma Kk Ｃ型慢性肝炎治療剤
KR20050088079A (ko) 2002-11-15 2005-09-01 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
CA2509955A1 (en) * 2002-11-29 2004-06-17 Gpc Biotech Ag Formulations useful against hepatitis c virus infections
MXPA05006230A (es) 2002-12-12 2005-09-20 Idenix Cayman Ltd Proceso para la produccion de nucleosidos ramificados-2'.
JP2006524227A (ja) * 2003-03-28 2006-10-26 ファーマセット，インク． フラビウイルス科ウイルス感染の治療のための化合物
ES2906207T3 (es) 2003-05-30 2022-04-13 Gilead Pharmasset Llc Análogos de nucleósidos fluorados modificados
WO2005007640A1 (ja) 2003-07-22 2005-01-27 Kyowa Hakko Kogyo Co., Ltd. ウィルス感染症の予防または治療用組成物
JP2007501185A (ja) 2003-07-25 2007-01-25 イデニクス（ケイマン）リミテツド Ｃ型肝炎を含むフラビウイルス関連疾患を治療するためのプリンヌクレオシド類似体
WO2005018330A1 (en) * 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
JP2005104852A (ja) * 2003-09-29 2005-04-21 Kyowa Hakko Kogyo Co Ltd モービリウィルス感染症の予防または治療用組成物
KR20070011451A (ko) 2004-05-05 2007-01-24 예일 유니버시티 신규의 항바이러스 헬리오크산틴 유사체
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
JP5001842B2 (ja) 2004-09-14 2012-08-15 ギリアド ファーマセット エルエルシー ２’−フルオロ−２’−アルキル−置換又は他の置換されていてもよいリボフラノシルピリミジン類及びプリン類並びにそれらの誘導体の製造
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
CU23432B6 (es) 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
JP5254033B2 (ja) 2005-12-23 2013-08-07 イデニク プハルマセウティカルス，インコーポレイテッド 分岐型ヌクレオシドを調製するための合成中間体の製造方法
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
NZ593648A (en) 2008-12-23 2013-09-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
BRPI0922508A8 (pt) 2008-12-23 2016-01-19 Pharmasset Inc Análogos de nucleosídeo
EP2376515A1 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Synthesis of purine nucleosides
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
CN102858790A (zh) 2010-03-31 2013-01-02 吉利德制药有限责任公司 核苷氨基磷酸酯
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
US10838095B2 (en) 2010-08-05 2020-11-17 Pgs Geophysical As Wavefield deghosting of seismic data recorded using multiple seismic sources at different water depths
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
US20150064253A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Combination formulation of two antiviral compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1526205A (en) * 1974-11-07 1978-09-27 Searle & Co Treatment of interferon-like material
US4100150A (en) * 1975-11-04 1978-07-11 G. D. Searle & Co. Stabilization of interferon against mechanical stress using thioctic acid
US4762705A (en) * 1981-11-10 1988-08-09 Adolf W. Schwimmer Cancer therapy with interferon
US4636383A (en) * 1984-08-29 1987-01-13 Schering Corporation Interferon-cyclaradine combination
US4927762A (en) * 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
CH666814A5 (it) * 1986-07-24 1988-08-31 Inpharzam Int Sa Composizione farmaceutica idrosolubile contenente n-acetil-cisteina.
CA1321349C (en) * 1986-11-21 1993-08-17 Robert Zimmerman Therapeutic combination of free-radical scavenger or metabolic inhibitor and biologically active protein
US4985241A (en) * 1986-11-21 1991-01-15 Cetus Corporation Therapeutic combination of free-radical scavenger and tumor necrosis factor
IT1231012B (it) * 1989-07-27 1991-11-08 Zambon Spa Composizione farmaceutica per uso orale contenente nac.
US5248697A (en) * 1990-09-20 1993-09-28 Brigham And Women's Hospital Enhancement of glutathione levels with glutamine
DK0486912T3 (da) * 1990-11-19 1996-03-18 Manz Galvano Technik Gmbh Spærre- og dræningsindretning for tromler til elektrolytisk eller kemisk overfladebehandling i bulk af genstande
JP2597953B2 (ja) 1991-12-10 1997-04-09 大塚製薬株式会社 制癌剤

Also Published As

Publication number Publication date
AU5707694A (en) 1994-07-19
DE69330032T2 (de) 2001-09-06
NO952469D0 (no) 1995-06-20
DE69330032D1 (de) 2001-04-19
IL108114A0 (en) 1994-04-12
EP0675730A1 (en) 1995-10-11
ITRM930840A0 (it) 1993-12-21
JPH08504799A (ja) 1996-05-21
WO1994014473A1 (en) 1994-07-07
GB9226729D0 (en) 1993-02-17
ATE199643T1 (de) 2001-03-15
HU9501841D0 (en) 1995-08-28
IL108114A (en) 1999-12-31
US5830455A (en) 1998-11-03
RU2145235C1 (ru) 2000-02-10
EP0675730B1 (en) 2001-03-14
HUT72965A (en) 1996-06-28
JPH06234657A (ja) 1994-08-23
CA2152389A1 (en) 1994-07-07
AU680858B2 (en) 1997-08-14
HRP931510A2 (en) 1995-12-31
ITRM930840A1 (it) 1995-06-21
MY141415A (en) 2010-04-30
YU79393A (sh) 1996-10-09
FR2699407A1 (fr) 1994-06-24
JP2849214B2 (ja) 1999-01-20
KR100309059B1 (ko) 2002-06-20
ZA939583B (en) 1995-05-22
PL309398A1 (en) 1995-10-02
CN1094642A (zh) 1994-11-09
ES2156150T3 (es) 2001-06-16
TW286283B (Sortimente) 1996-09-21
NO952469L (no) 1995-06-20

Similar Documents

Publication Publication Date Title
IT1261949B (it) Composizione terapeutica a base di interferone umano, impiego di interferone umano in tale composizione e relativo metodo.
IL119461A (en) 4,7-disubstituted -7H-pyrrolo ¬2, 3-d¾pyrimidines
EP0663836A1 (en) TREATMENT OF AUTOIMMUNE AND INFLAMMATION DISEASES.
IL134345A0 (en) Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
IL105724A (en) PURIFIED FORMS OF DNase
GB9806632D0 (en) Peptide factor
DE69309698D1 (de) Hautbehandlung mit adhäsionsverstärkenden eigenschaften
MX9203319A (es) Metodo para la preparacion de cristales de alfa-2 interferona.
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
IT1264965B1 (it) Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce
SE9601395D0 (sv) New therapeutic treatment 1
ES2068714T3 (es) Derivados de pirimidina para aumentar la actividad antitumoral.
IT1271567B (it) Procedimento per l'ulteriore trattamento di salcicce
ATE155345T1 (de) Gegengift immunsera
HUT75528A (en) Use of dimeticone for treating aphthae and stomatitis
IT1288399B1 (it) Medicamento per il trattamento terapeutico della maculopatia legata all'eta', della maculopatia non legata all'eta' e per la profilassi
DE69803298D1 (de) Verwendung des wachstumshormons in mitteln zur behandlung der insulinresistenz im herzen
IT1252659B (it) Procedimento per la depurazione dell'1,1,1-trifluoro-2-fluoroetano e dell'1,1,1-trifluoro-2,2-dicloroetano
MX9205978A (es) Nuevas proteinas inhibidoras de trombina de garrapatas.
PL375354A1 (en) Use of treosulfan and derivatives thereof for treating multiple sclerosis
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
ITMI922766A1 (it) Impiego di lisolecitine nel trattamento della impotenza maschile e dell'alopecia e relative composizioni atte a tale impiego.
NO900121L (no) Probursin.
ITFI920241A0 (it) Impiego della melatonina nella terapia della sclerosi sistematica, della sarcoidosi ed altro
ITRM920516A0 (it) Composizione e suo uso per il trattamento terapeutico di affezioni dermatitiche, particolarmente la psoriasi.

Legal Events

Date Code Title Description
0001 Granted